Sowa Hideaki, Hamaya Etsuro, Yamamoto Takanori
Medical Science, Lilly Research Laboratories Japan, Eli Lilly Japan KK.
Clin Calcium. 2011 Jan;21(1):9-16.
Teriparatide is a preparation of human parathyroid hormone (PTH) (1-34). It has been approved as an agent for stimulating bone formation in many foreign countries, including Europe and the United States. In Japan, it was approved in July this year. In nonclinical studies, teriparatide was shown to have a unique bone formation-stimulating effect not seen in existing drugs. In domestic and overseas clinical studies, teriparatide was shown to have strong effects in increasing BMD, promoting remodeling of bone microstructure and suppressing the onset of fracture. Furthermore, teriparatide can increase BMD through stimulation of bone formation regardless of the nature of prior treatment or the presence/absence of responses to prior treatment. With these features, teriparatide is expected to serve as a first-line drug for management of patients with osteoporosis at elevated risk for fracture.
特立帕肽是一种人甲状旁腺激素（PTH）（1-34）制剂。它在包括欧洲和美国在内的许多国家已被批准作为一种刺激骨形成的药物。在日本，它于今年7月获得批准。在非临床研究中，特立帕肽显示出具有现有药物中未见的独特骨形成刺激作用。在国内外临床研究中，特立帕肽显示出在增加骨密度、促进骨微结构重塑和抑制骨折发生方面有强大作用。此外，无论先前治疗的性质如何或对先前治疗有无反应，特立帕肽都可通过刺激骨形成来增加骨密度。具有这些特性，特立帕肽有望成为治疗骨折风险升高的骨质疏松症患者的一线药物。
